Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for
Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings
02:00am, Friday, 03'rd Sep 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (S
Tiziana Life Sciences races at US open after exclusive licensing agreement with Precision BioSciences
10:23am, Thursday, 02'nd Sep 2021
Shares in Tiziana Life Sciences PLC raced 20% higher in the opening minutes of trading on Wall Street after the group inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). T
Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications
09:42am, Thursday, 02'nd Sep 2021
Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's foralumab. The companies plan to explore the full
Tiziana Life Sciences surges on exclusive licensing agreement with Precision BioSciences
06:53am, Thursday, 02'nd Sep 2021
Tiziana Life Sciences PLC surged 19% to 73p after signing an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The pair will explore the use of Tiziana's foralumab monoclonal ant
Tiziana Life Sciences inks exclusive licensing deal with US group Precision BioSciences that takes it into CAR-T therapy
02:55am, Thursday, 02'nd Sep 2021
Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it has inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) to explore the use of Tiziana's foralumab monoclonal antib
Precision Gains Access to Tiziana's Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio Precision Gains Access to Tiziana's Anti-CD3 Antibody, Fora
Tiziana Life Sciences set for Nasdaq move
06:08am, Friday, 20'th Aug 2021
Tiziana Life Sciences Plc told investors it has formally begun its strategic plan to change its corporate structure. It has established a Bermuda-incorporated company Tiziana Life Sciences Ltd which i
LONDON and NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inf
Los Angeles, California--(Newsfile Corp. - August 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Te
A peer-reviewed scientific article has underscored the potential of Tiziana Life Sciences PLC (LSE:TILS, NASDAQ:TLSA, FRA:RTRA, OTC:TIZAF)'s monoclonal antibody nasal spray in people with mild-to-mode
Tiziana Life Sciences upbeat on potential for coronavirus treatment
02:45am, Tuesday, 17'th Aug 2021
How it is doing Shares have soared recently on the potential for Tiziana's (LON:TILS) TZLS-501 to be useful for people severely ill with coronavirus-related complications. TZLS-501 is a class of monoc
A peer-reviewed scientific article has underscored the potential of Tiziana Life Sciences PLC's (NASDAQ:TLSA, LON:TILS) monoclonal antibody nasal spray in people with mild-to-moderate Covid. The repor
NEW YORK and LONDON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for
Tiziana Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit
01:14pm, Monday, 16'th Aug 2021
London, United Kingdom--(Newsfile Corp. - August 16, 2021) - Tiziana Life Sciences plc (NASDAQ:TLSA) today announced that Dr. Kunwar Shailubhai, CEO & CSO will be attending the Q3 Virtual Investor Sum
